SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently facing intense selling pressure and market skepticism as participants debate whether the asset is in a long-term decline or merely experiencing a major shakeout. While some investors are accumulating on the dip, pointing to rising staking demand and institutional tokenization projects, the broader community remains divided, with many expressing deep frustration over prolonged sideways price action and perceived manipulation by market makers.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent Biosolutions is capturing investor attention as the market evaluates the company's turnaround progress and potential for contract awards against the backdrop of increased demand for medical countermeasures. The community is actively debating the company's debt management strategies and long-term viability, with many closely watching for signs of strategic shifts or partnerships that could impact future valuation.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors digest the company's strategic decision to split its business into two dedicated units to sustain growth as its blockbuster cancer therapy, Keytruda, approaches a significant patent cliff. Market conversation is currently dominated by debate over this long-term structural pivot, the potential for targeted pipeline expansion, and whether these internal adjustments will successfully offset looming revenue headwinds.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron is trending following positive analyst attention and strategic pipeline updates, while investors closely monitor regulatory developments regarding the company's manufacturing partnerships. The community remains focused on the long-term potential of the product portfolio and recent share price stability as a key indicator of underlying value.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space Inc is experiencing extreme volatility as retail investors debate the company's long-term viability amid concerns over leadership disputes, delayed financial filings, and intense short-selling pressure. While some community members remain optimistic about a potential short squeeze and exposure to the broader space sector growth, others are actively warning of potential dilution and highlighting the company's lack of consistent revenue.

Futu Holdings Ltd. engages in the provision of digitalized financial services. It offers securities brokerage and wealth management products. The company was founded by Leaf Hua Li in December 2007 and is headquartered in Hong Kong.

Futu Holdings Ltd - ADR

Futu Holdings is trending as investors digest the company's latest earnings report and a significant regulatory fine from Chinese authorities regarding its cross-border operations. While the community is actively debating the severity of the enforcement and its long-term impact on the firm's growth outside of mainland China, many remain focused on the potential for an oversold bounce given the company's fundamental performance.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is currently at the center of intense debate as traders weigh its role in the critical supply chain for indium phosphide wafers against a massive surge in valuation that many observers characterize as a speculative bubble. While some market participants highlight the company's position as a bottleneck provider in the AI infrastructure stack, skeptics point to insider selling and a significant disconnect between current share prices and historical profitability as key risks.

Blacksky Technology, Inc. is a space-based intelligence company, which engages in the business of delivering real-time imagery, analytics, and high-frequency monitoring of most critical and strategic locations, economic assets, and events. The firm is also involved in providing geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems to government and commercial customers. The company was founded in 2014 and is headquartered in Herndon, VA.

BlackSky Technology Inc - Ordinary Shares - Class A

BlackSky Technology is trending as investors react to a new multi-year government contract and the commissioning of its latest satellite, even as debates persist regarding dilution risks from potential share offerings. The community remains hyper-focused on the company's role within the broader space economy and its ability to convert a growing backlog into high-margin revenue.

Hyliion Holdings Corp. engages in the development of sustainable electricity-producing technology. It focuses on providing modular power plant technology that can operate on various fuel sources through the KARNO power module. The company was founded by Thomas J. Healy in 2015 and is headquartered in Cedar Park, TX.

Hyliion Holdings Corporation - Ordinary Shares - Class A

Hyliion Holdings Corp

Hyliion is seeing significant market interest driven by the successful testing of its fuel-agnostic KARNO power module and recent progress in U.S. Navy and military validation trials. Community discussion remains focused on the potential for institutional accumulation and whether the company can successfully convert its large pipeline of non-binding letters of intent into finalized commercial revenue.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing strong market momentum as investors pivot toward its QNX software as a foundational play for physical AI and robotics, fueling a surge in volume and sentiment. The community is actively discussing a potential long-term rerating, with many long-term shareholders celebrating this price action as the beginning of a sustained turnaround.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients

DYN shares jump 10% after launching a phase III study of z-rostudirsen in Duchenne muscular dystrophy patients amenable to exon 51 skipping.

DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside

Equity

Dyne said it plans to submit an application seeking accelerated approval of z-rostudirsen to the U.S. Food and Drug Administration later this quarter.


Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

Key PointsSaturn V sold 822,007 shares of Dyne Therapeutics in the first quarter; the estimated transaction value was $14.17 million based on quarterly average prices...

Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know

Dyne Therapeutics (DYN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Dyne Therapeutics Q1 Net Loss Widens

(RTTNews) - Dyne Therapeutics, Inc. (DYN) reported Monday that net loss for the first quarter was $120.85 million or $0.73 per share, compared to net loss of $115.36 million or $1.05 per share in the prior-year quarter...

Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 11,600 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 11,600 shares of the business's stock in a transaction on Tuesday, May 5th. The shares were sold at an average price...

Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 11,904 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 11,904 shares of the company's stock in a transaction on Monday, May 4th. The stock was sold at an average price of...

Wall Street Zen Downgrades Dyne Therapeutics (NASDAQ:DYN) to Strong Sell

Wall Street Zen lowered shares of Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday...

Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells 227,337 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 227,337 shares of the company's stock in a transaction on Tuesday, April 28th. The shares were sold at an average...

Jason Rhodes Sells 73,108 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 73,108 shares of the stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of...

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Current Price	$17.37
Prev Close	$17.37
Open	$17.21
Dividend Yield	0.00%
50-Day Moving Average	$18.26
Beta	1.90
Avg. Volume	1.75M
PE Ratio	-5.38

52-Week High	$25.00
52-Week Low	$8.06
Market Capitalization	$2.87B
EPS (Annual)	-$3.47
Price to Book	3.32
Revenue Per Employee	$0.00

DYN
Dyne Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest DYN News

DYNDyne Therapeutics Inc